VitaGraft KidneyTM quantifies the amount of DNA fragments in transplant patients' blood that originate from the donor organ, a key biomarker for assessing graft health. This process is commonly referred to as donor-derived cell-free DNA (dd-cfDNA) testing and is widely used in clinical practice today. In this latest study, Oncocyte's proprietary diagnostic dd-cfDNA test using digital PCR was able to diagnose antibody-mediated rejection (AMR) in kidney transplant recipients nearly a year ahead of standard protocols 1 . "We are excited to see our dd-cfDNA technology demonstrate strong predictive value for AMR, supporting clinicians in identifying AMR in patients sooner, thereby enhancing the opportunity for better outcomes,” said Oncocyte Chief Science Officer Dr. Ekkehard Schuetz. "The trial's results further validate dd-cfDNA as a critical biomarker that can bridge diagnostic gaps for transplant patients.” For further context, de-novo donor specific antibody (dnDSA) is a routine biomarker used in kidney transplant management. The appearance of dnDSA in a patient -- that is, the patient is found to be dnDSA-positive (dnDSA+) -- signals an increased risk of AMR. This latest study shows that compared to standard of care, VitaGraft Kidney can significantly reduce the time to diagnosis of AMR in dnDSA+ patients. It is also the first randomized interventional study to validate any dd-cfDNA technology as a rule-in test for biopsy in a high-risk population. Catching AMR early, when kidney graft loss can be minimized, is becoming increasingly important as physicians explore the use of drugs, including the anti-CD38 drugs felzartamab and daratumumab, to manage rejection. Monitoring with VitaGraft in this high-risk patient population could support early intervention with these new therapeutic options. Once patients are on therapy, monitoring for therapeutic efficacy is also important to manage potential unwanted side effects. Publications using VitaGraft to monitor for efficacy for both aforementioned drugs can be found in the New England Journal of Medicine and Transplant International . In addition, earlier this year, Oncocyte signed an agreement with a European biotechnology company to be the provider of dd-cfDNA testing for a Phase II clinical trial for a separate therapeutic in AMR. Oncocyte expects to submit for claims expansion to its payor, MolDX 2 , to support the use of VitaGraft for these high-risk patients in the clinic. If granted, it would expand the use case beyond the current for-cause claim, opening significant new revenue opportunities. In sum, this clinical trial provides compelling evidence for dd-cfDNA monitoring as a tool for enhancing early intervention and improving outcomes for patients at increased risk of transplant rejection. Oncocyte scientists and inventors of the technology, Dr. Schuetz, Julia Beck and Kirsten Bornemann-Kolatzki, co-authored the study, which was initiated by researchers at Charité - Universitätsmedizin Berlin under the leadership of Prof. Klemens Budde. The study was published in Nephrology Dialysis Transplantation: Oxford Academic and may be found by accessing this link. Additional study details: Highlighting potential for improved patient outcomes, as well as implications for broader clinical applications and future therapies The interventional randomized trial, conducted between June 2021 and July 2023, involved 40 kidney transplant recipients with dnDSA, assessing longitudinal dd-cfDNA monitoring as a guiding tool for diagnostic biopsy compared to standard clinical practices. Oncocyte's proprietary dd-cfDNA technology was able to detect the onset of AMR significantly earlier in patients by guiding the indication for biopsy (median time from inclusion to diagnosis: 2.8 months) compared to the control group using standard of care (14.5 months). As noted above, this early intervention could offer a valuable advantage in transplant care by enabling prompt treatment before irreversible damage occurs. "This study underscores the impact of dd-cfDNA as a critical biomarker for early AMR detection, providing healthcare teams with timely data enabling them to initiate treatments sooner," said Dr. Aylin Akifova, first author from Charité. This study also suggests that dd-cfDNA monitoring could also be instrumental in identifying subclinical AMR-a silent condition that, if undiagnosed, can lead to significant graft damage. Additionally, the findings come at a crucial time, as mentioned above, as promising new treatments, including CD38-targeted therapies, are showing unprecedented efficacy in treating AMR. Early diagnosis with dd-cfDNA could provide the earliest window for intervention, offering an advantage for patients suffering from AMR, a disease with historically very limited treatment options. "We congratulate Charité's research teams on these compelling findings, which further underscore our mission to empower clinicians with tools for precision diagnostics while also democratizing access to novel molecular diagnostic testing to improve patient outcomes,” said Josh Riggs, CEO of Oncocyte. "We look forward to expanding the clinical applications of dd-cfDNA technology and supporting transplant communities worldwide with our innovative diagnostic solutions.” About Oncocyte Oncocyte is a diagnostics technology company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraftTM is a clinical blood-based solid organ transplantation monitoring test. GraftAssureTM is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIOTM is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNITM is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/ . For more information about our products, please visit the following web pages: VitaGraft KidneyTM - https://oncocyte.com/vitagraft-kidney/ VitaGraft LiverTM - https://oncocyte.com/vitagraft-liver/ GraftAssureTM - https://oncocyte.com/graftassure/ DetermaIOTM - https://oncocyte.com/determa-io/ DetermaCNITM - https://oncocyte.com/determa-cni/ VitaGraftTM, GraftAssureTM, DetermaIOTM, and DetermaCNITM are trademarks of Oncocyte Corporation. CONTACT: Jeff Ramson PCG Advisory (646) 863-6893 [email protected] Forward-Looking Statements Any statements that are not historical fact (including but not limited to statements that contain words such as "will,” "believes,” "plans,” "anticipates,” "expects,” "estimates,” "may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the expectation that Oncocyte will submit for claims expansion to MolDX to support the use of VitaGraft for high-risk patients in the clinic, which may expand the use case and open significant new revenue opportunities, the company's anticipated expansion of clinical applications of dd-cfDNA technology, the company's goal to support transplant communities worldwide with its innovative diagnostic solutions, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors” and other cautionary statements found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

The AP Top 25 men’s college basketball poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . LAWRENCEVILLE, N.J. (AP) — Cavan Reilly’s 18 points helped Delaware defeat Rider 72-66 on Saturday. Reilly went 6 of 12 from the field (4 for 10 from 3-point range) for the Fightin’ Blue Hens (4-3). Izaiah Pasha added 15 points while finishing 7 of 10 from the floor and also had six rebounds. Erik Timko shot 5 for 9, including 3 for 7 from beyond the arc to finish with 15 points. Jay Alvarez led the Broncs (4-4) in scoring, finishing with 17 points and six rebounds. TJ Weeks Jr. added 15 points, eight rebounds and two steals for Rider. Tariq Ingraham also put up 12 points and 11 rebounds. ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .The alleged perpetrator of the deadly car-ramming attack on a Christmas market in Germany had been contacted by police just weeks before the incident. or signup to continue reading The attack in the central city of Magdeburg on Friday evening, which killed five people including a nine-year-old boy, is believed to have been carried out by a Saudi national identified only as Taleb A according to German privacy laws. The number of people injured in the rampage has climbed to 235. The suspect has been living in Germany since 2006 and was granted political refugee status in 2016. He was most recently working as a doctor in the town of Bernburg, south of Magdeburg. Taleb A was detained at the scene and is being held in police custody, with investigators searching for a motive amid suggestions that authorities failed to heed warnings about the man. Tamara Zieschang, the interior minister of the eastern state of Saxony-Anhalt, told MPs in Magdeburg on Monday that police met the man twice - in September 2023 and October 2024 - to warn him about his behaviour. Meanwhile, the Interior Ministry of the northern state of Mecklenburg-Vorpommern said that Taleb A became known to authorities as a potential suspect in 2015. Regional authorities had informed the Federal Criminal Police Office at the Joint Counter-Terrorism Centre, which is supported by Germany's federal and regional government, about the man's possible intention to carry out an attack on February 6, 2015, it said. The report concerned threats to carry out actions that would attract international attention against a medical association in Mecklenburg-Vorpommern in April 2013 and one year later against a local authority in the northern German city of Stralsund. The Mecklenburg-Vorpommern interior minister, Christian Pegel, said the 50-year-old suspect had lived in the state from 2011-16 and had completed parts of his specialist medical training in Stralsund. He said the man had been involved in a dispute with the medical association about the recognition of examination results and had later threatened the social services in Stralsund in an attempt to obtain assistance with living costs. A district court fined Taleb A for threatening the medical association, Pegel said. However, he added, the previous investigations had not revealed any evidence of real preparations for an attack or Islamist connections. The man was warned by the police and told that he would be monitored more closely but was not classified as a threat, Pegel said. Advertisement Sign up for our newsletter to stay up to date. We care about the protection of your data. Read our . AdvertisementNone

IRVINE, Calif.--(BUSINESS WIRE)--Nov 21, 2024-- Sims Lifecycle Services (SLS) has once again been recognized as a Representative Vendor in the 2024 Gartner® “Market Guide for IT Asset Disposition. 1 ” In our opinion, this acknowledgment, our fifth inclusion in the Market Guide 2, highlights SLS's commitment to delivering world-class IT asset management and disposition solutions that meet the highest standards of data security, sustainability, compliance and value return. We feel this recognition of SLS as a Representative Vendor underscores the company's strong position in the market and our ability to support global clients in managing the end-of-life cycle of IT assets. According to Gartner, “Sustainability requirements are compounding the ongoing ITAD challenges of data security and sound reuse/recycling. Sourcing, procurement and vendor management leaders can use this Market Guide to navigate the ITAD market, assess growing compliance risks and identify representative ITAD providers.” "In our view, being included again as a Representative Vendor in the 2024 Gartner® “Market Guide for IT Asset Disposition” is not just a recognition, it’s a validation of our commitment to excellence and innovation in IT asset disposition,” notes Sean Magann, chief commercial officer at Sims Lifecycle Services. “We believe this inclusion highlights our ability to innovate in ways that not only safeguard our clients’ data but also drive sustainability and efficiency. It’s proof that we’re not just adapting to change, we’re leading it.” While inadequate data security and environmentally harmful recycling continue to be the biggest risks within the ITAD market, the report focuses largely on the financial and environmental advantages of device reuse and states that “ITAD is increasingly focused on the environmental sustainability benefits of extending the lifecycle of technology assets to reduce greenhouse gas (GHG) emissions and e-waste.” Refurbishment and redeployment of IT devices is expected to increase as organizations more fully recognize the carbon avoidance realized versus recycling. “ITAD,” the report maintains, “is crucial for IT sustainability, mitigating Scope 3 emissions and supporting the circular economy.” Gartner urges corporations to utilize industry-best ITAD vendors to “leverage the superior environmental sustainability (and budget) characteristics of asset reuse as your primary disposition process.” About Sims Lifecycle Services Sims Lifecycle Services provides solutions to extend the life of data center and enterprise IT assets, and the company recognizes the value in end-of-life electronics, components and materials. SLS works with hyperscale and cloud data centers to reuse and redeploy data center equipment. Fortune 500 companies are supported by SLS to navigate ongoing technology shifts by securely and responsibly managing the disposition of IT equipment and recycling of electronic products. IT asset disposition (ITAD) and electronics recycling services offered at SLS support the evolution of the electronics industry movement toward circularity. SLS clients benefit from data security, maximum IT value recovery, global compliance and sustainable IT use. As a responsible corporate citizen, and in alignment with the United Nations Sustainable Development Goals, we continuously seek new ways to contribute to the circular economy. Visit the SLS website, www.simslifecycle.com for more information on the company’s global coverage and services offered or for media contact email: sls.media@simsmm.com . Notes: 1 Gartner, Market Guide for IT Asset Disposition, By Rob Schafer, Christopher Dixon, Autumn Stanish, 6 November, 2024 2 Sims Lifecycle Services (SLS) was recognized as Sims Recycling Solutions in 2018 and 2016. Gartner, Marketing Guide for IT Asset Disposition, 22 November 2016 Gartner, Marketing Guide for IT Asset Disposition, 26 July 2018 Gartner, Marketing Guide for IT Asset Disposition, 30 November 2020 Gartner, Marketing Guide for IT Asset Disposition, 23 January 2023 Required Disclaimer: GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. View source version on businesswire.com : https://www.businesswire.com/news/home/20241121451696/en/ sls.media@simsmm.com KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SUSTAINABILITY ENVIRONMENT HARDWARE DATA MANAGEMENT RECYCLING TECHNOLOGY OTHER TECHNOLOGY SECURITY SOURCE: Sims Lifecycle Services Copyright Business Wire 2024. PUB: 11/21/2024 06:01 PM/DISC: 11/21/2024 06:00 PM http://www.businesswire.com/news/home/20241121451696/en

None

Arcadium Lithium Announces Shareholder Approval of Proposed Rio Tinto Transaction and Provides Regulatory UpdateWith rookie QB Penix showing poise in starting debut, the Falcons again control their playoff hopes